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Background: Chronic radicular pain can be effectively treated with spinal cord stimulation, but this therapy is not
always sufficient for chronic back pain. Subcutaneous nerve stimulation (SQS) refers to the placement of
percutaneous leads in the subcutaneous tissue within the area of pain. Case series data show that failed back
surgery syndrome (FBSS) patients experience clinically important levels of pain relief following SQS and may also
reduce their levels of analgesic therapy and experience functional well-being. However, to date, there is no
randomized controlled trial evidence to support the use of SQS in FBSS.
Methods/Design: The SubQStim study is a multicenter randomized controlled trial comparing SQS plus
optimized medical management (‘SQS arm’) versus optimized medical management alone (‘OMM arm’) in patients
with predominant back pain due to FBSS. Up to 400 patients will be recruited from approximately 33 centers in
Europe and Australia and will be randomized 1:1 to the SQS or OMM arms. After 9 months, patients who fail to
reach the primary outcome will be allowed to switch treatments. Patients will be evaluated at baseline (prior to
randomization) and at 1, 3, 6, 9, 12, 18, 24, and 36 months after randomization. The primary outcome is the
proportion of patients at 9 months with a ≥50% reduction in back pain intensity compared to baseline. The
secondary outcomes are: back and leg pain intensity score, functional disability, health-related quality of life, patient
satisfaction, patient global impression of change, healthcare resource utilization/costs, cost-effectiveness analysis
and adverse events. Outcomes arms will be compared between SQS and OMM arms at all evaluation points up to
and including 9 months. After the 9-month assessment visit, the main analytic focus will be to compare within
patient changes in outcomes relative to baseline.
Discussion: The SubQStim trial began patient recruitment in November 2012. Recruitment is expected to close in
late 2014.
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Chronic back and leg pain (CBLP) is a diffusely defined
group of pain conditions, ranging from chronic low back
(‘axial’) pain to persisting hip, buttock and leg (‘radicu-
lar’) pain and often consists of a combination of both
[1]. It is estimated that 10% to 40% of patients who have
undergone lumbar spine surgery still experience CBLP:
the so-called ‘failed back surgery syndrome’ (FBSS).
CBLP and FBSS can be very difficult to manage for pa-
tients and clinicians and is associated with substantive
negative impact on a patient’s health-related quality and
well-being [2,3]. Furthermore, the management of CBLP
places a high economic burden on both healthcare sys-
tems and society [4].
Greater success has been reported in the treatment of
patients with CBLP and FBSS that present with radicular
(or leg) pain rather than with axial (or low back) pain
[5,6]. Randomized controlled trials (RCTs) have shown
spinal cord stimulation to be a clinically effective adjunct
to medical management and an alternative to a further
operation in FBSS [7,8]. However, these studies have
been limited to individuals who presented with predom-
inant leg pain, excluding those with a chief issue of axial
pain exceeding radicular pain. Other therapies have been
applied to FBSS presenting as predominant back pain in-
cluding peripheral neuromodulation.
Peripheral neuromodulation includes two distinct tech-
nical approaches: the lead can be placed percutaneously or
via an open surgical technique. Peripheral nerve stimula-
tion (PNS) utilizing an open surgical technique was first
reported in 1967 [9]. This technique involves the use of a
device to provide stimulation to a single peripheral
nerve, with the goal of producing stimulation-induced
paresthesia and relief of pain within the sensory distri-
bution of that nerve [9,10]. Subcutaneous stimulation
(SQS) (also known as ‘peripheral nerve field stimulation’
or ‘regional field stimulation’ or ‘target field stimula-
tion’), a more recent advance in neuromodulation, tar-
gets not a single nerve, but rather the area of pain
perception itself. In SQS, percutaneous leads are placed
in the subcutaneous tissue within the area of pain per-
ception. The mechanism of SQS-mediated paresthesia
remains to be fully elucidated. However, it is thought
that its effect arises from the creation of an electrical
field that results in decreased nociceptive input which
may impact on local blood flow, block cell membrane
depolarization, and/or alter neurotransmitter release
and reuptake, thus altering nociceptive information as it
is transmitted to the central nervous system [11].
The remainder of this paper focuses on SQS.
Systematic review
To the best of our knowledge, no previous systematic re-
view of SQS for CBLP or FBSS has been published. We,therefore, undertook a comprehensive search of a number
of electronic databases including MEDLINE, EMBASE
and the Cochrane Library. Our search included a combin-
ation of Medical Subject Headings that included: ‘failed
back surgery syndrome’, OR ‘back pain’ OR ‘chronic leg
pain’ OR ‘post laminectomy’AND ‘peripheral nerve stimu-
lation’ OR ‘electric stimulation’ OR ‘subcutaneous stimula-
tion’. Issues of ‘Neuromodulation’ were hand searched
and the reference list checked from the Medtronic dossier
of evidence of peripheral nerve stimulation that was sub-
mitted to the TuV in 2011 for purposes of obtaining
Conformité Européenne (CE) Mark for percutaneous PNS
[unpublished results].
The study selection process is shown in Additional file 1:
Figure S1. Our searches identified 1,030 citations up to
June 2012. Following exclusions (that is, non-English pub-
lications, hybrid SQS and spinal cord stimulation (SCS)
systems, non-CBLP or FBSS indications, case reports and
studies published only as abstracts) we identified eight
studies (nine publications) that reported efficacy and
device-related complication outcomes with SQS (see
Table 1) [12-20]. Study selection, data extraction and qual-
ity assessment was undertaken by a single author and then
checked for accuracy by a second.
All included studies employed a case series design
(that is, reported outcomes in a cohort of patients before
and after SQS and no control group) and included a
total of 191 patients with CBLP implanted with SQS, of
which a proportion of patients experienced CBLP fol-
lowing lumbar surgery, that is, FBSS. Although the pre-
cise location of pain was often not clearly stated, studies
appear to recruit patients specifically with a back com-
ponent of pain. Only one study explicitly stated that they
included individuals with both back and leg pain [20].
Studies assessed outcomes before and after SQS im-
plantation, with follow-up ranging from 3 to 12 months.
The quality of included studies was assessed on the
basis of the following five criteria: (1) prospective design,
(2) consecutive or random sampling, (3) explicit state-
ment of inclusion/exclusion criteria, (4) independent
outcome assessment and (5) clear statement of loss to
follow-up/withdrawals [21]. Details of study method-
ology were generally poorly reported and limited our
ability to assess study quality. A table summarizing qual-
ity assessment is provided as Additional file 1: Table S1.
Studies consistently reported that patients experienced
pain relief following SQS implantation (see Table 2).
Across the 6 studies reporting pain visual analog scale
(VAS) values, the average baseline score varied from 6.8 to
9.1 (on a 10-point scale) [13-16,18,20]. Following SQS, the
reduction in mean VAS ranged from 4.2 to 1.7. Five stud-
ies also reported improvements in the level of analgesia
medication, [14,17-20] and three reported improvements
in functional capacity compared to before SQS [13,16,18].
Table 1 Systematic review: summary of characteristics of included studies
Study Population
Lead author (year),
reference, country, type
and recruitment dates
Study design Implanted N
(tested N)
Description (as stated by authors)
and indication
Age, gender,
post back
surgery
Baseline
VAS/NRSa
Burgher [17] USA, single
center, August 2009 to
December 2010
Retrospective
case series
6 (10) ‘Axial back and neck pain’ Mean 53 years,
20% male, not
reported
Not
reported
‘All patients had failed more conservative
treatment…’
All predominantly axial pain
Campbell [12] USA, single
center, July 1974 to
August 1975
Case series 10 (NR) ‘Low back pain syndrome with sciatica’ Mean 48 years,
20% male, not
reported
Not
reported
‘Persistent disabling pain despite all traditional
medical and surgery’
Falco [16] USA, single center,
August 2008 to April 2009
Case series 18b (28) ‘Chronic [non-appendicular] pain that had not
responded to conservative or surgical treatment
and whose pain significantly impacted their quality
of life’
Mean 56 years,
28% male, not
reported
Mean 9.1
‘Many of the patients had multiple sources and
areas of chronic pain for years’
‘…in several cases, [failed] lumbar spine surgery.’
Paicius [13] USA, single
center. May 2005 to
September 2006
Case series 6 (NR) ‘History of chronic low back pain’ Mean 63 years,
50% male, 83%
Mean 9.1
Majority of patients followed lumbar surgery
Sator-Katzenchlager [14]
Austria, multicenter June
1999 to February 2007
Retrospective
case series
66c (NR) ‘Failed back surgery syndrome’ and ‘low back pain’ Mean 59 years,
48% male, 56%
Mean 8.2
‘Prior failure of systemic or less invasive
\treatments….and no indication for further surgery’
Verrills [15,19] Australia, single
center, dates not reported
Retrospective
case series
23b (NR) ‘Failure to respond to conservative treatment….
almost all patients had also failed surgical
procedures’
Mean 58 years,
39% male, not
reported
Not
reported
‘Low back pain’
Verrills [18,19] Australia, single
center, dates not reported
Prospective
case series
44d (NR) ‘Lumbrosacral pain’ Range 27 to 88
years, 43% male,
not reported
Mean 8.1
‘Failure to respond to other conservative therapy’
Yakovlev [20] USA, single
center August 2007 to
July 2009
Retrospective
case series
18 (NR) ‘Chronic low back and lower extremity pain
associated with PLS after multilevel spinal surgical
procedures’
Mean 62 years,
61% male, 100%
12
Population indicates number of patients with CLBP pain unless other stated.
a0 to 10 scale.
bMixed indication case series: unclear N CLBP/FBSS.
bMixed indication case series of N = 111.
dMixed indication case series of N = 100.
(C)LBP (chronic) low back pain, FBSS failed back surgery syndrome, NR not reported, NRS numeric rating scale, PLS post laminectomy syndrome, VAS visual
analog scale.
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studies. Across the 3 studies reporting data, a total of 41
out of 224 (18%) patients experienced 1 or more device-
related complication [14,18,19]. Risks of specific compli-
cations were as follows: lead migration, 19/245 (8%, 5
studies [14,16-19]); other lead complications (for ex-
ample, fracture), 10/211 (5%, 2 studies [14,19]); hardware
erosion, 0/13 (0%, 1 study [10]); infection, 9/258 (3.5%, 6
studies [12,14,17-20]); and device migration 1/113 (<1%,
2 studies [12,19]).
In summary, our systematic review identified a grow-
ing body of international prospective and retrospective
case series data showing that CBLP and FBSS patients
experience pain relief following SQS, a reduction in theiranalgesic therapy and an improvement in functional
well-being over the short to medium term. The reduc-
tion in pain observed across studies compares favorably
with the clinically important change of two or more
units (on a scale of 0 to 10) cited by the IMMPACT
(‘Initiative on Methods, Measurement, and Pain Assess-
ment in Clinical Trials’) guidelines on outcome mea-
sures for pain trials [21]. Furthermore, SQS appears to
be associated with a level of device-related complications
similar, or lower, to that seen with spinal cord stimula-
tion [22,23]. However, given the current absence of level
I clinical and economic evidence for SQS, this overview
supports the urgent need for a well-conducted RCT and
parallel economic evaluation.
Table 2 Systematic review: summary of efficacy results
Lead author,
year and
reference
Follow-up Pain outcome Other outcomes
Pre-VAS/NRS,
mean (SD)
Post-VAS/NRS, mean
(SD), P valuea
Percentage pain
relief
Burgher [17] Mean 4.5
months
Not reported Not reported Mean 45% (range:
20 to 80%) (n = 10)
All patients reported to be ‘somewhat’ or
‘very satisfied’ with outcome; 1/6 patients
reported reduction in opiate intake
Campbell [12] Mean 12.8
months
Not reported Not reported Not reported 0/10 achieved ‘excellent’ outcome on pain
relief; 2/10 achieved ‘partial success’ of
pain relief; 8/10 ‘failure’ of pain relief
Falco [16] Mean 3
months
9.1 (1.1) (n = 18) 1.2 (1.0) (n = 18),
<0.0001a
Not reported Pain medication usage dropped in 18/18
patients with 7/18 taking no pain
medication; ODI: before treatment, mean
33.6 (SD 6.4) and after treatment, mean
19.7 (9.0)
Paicius [13] Not reported 6.8 (2.3) (n = 6) 2.5 (0.6) (n = 4), 0.07ab Not reported ‘All patients experienced a significant….
increase in their ability to function’
Sator-Katzenchlager
[14]
3 months FBSS 8.0 (1.4)
(n = 37); LBP 8.3
(0.9) (n = 29)
FBSS 3.3 (2.1),
<0.0001; LBP 4.2 (2.2)
(n = 29), <0.0001
Not reported Significant reduction in WHO analgesic
medication score
Verrills [15,19] Mean 7.6
months
7.5 (1.2) (n = 28) 3.5 (2.0)
(n = 28), <0.05
Mean 60% 16/23
(70%) ≥50% pain
relief
2/23 (7%) increased capacity to perform
work; 16/23 (70%) reduced analgesia;
20/23 (87%) ‘satisfied’ or better
Verrills [18,19] Mean 7.2
months
7.0 (1.3) (n = 44) 3.7 (2.6) (n = 44),
<0.0001ab
Not reported Significant improvement (P <0.03) in
disability as assessed by ODI
Yakovlev [20] 1 and 12
months
7.4 (1.0) (n = 18) 1 month 2.6 (0.8)
(n = 18), <0.0001ab; 12
months 1.7 (0.6)
(n = 18), <0.0001ab
18/18 (100%) ≥50%
pain relief at 1 and
12 months
Decreased or discontinued use of pain
medication 16/18 (89%)
aP value for pre/post treatment comparison.
bPaired t test undertaken by authors of the present report.
FBSS failed back surgery syndrome, LBP low back pain, NRS numeric rating scale, ODI Oswestry Disability Index, VAS visual analog scale, WHO World
Health Organization.
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The SubQStim study is a multicenter RCT comparing
the clinical effectiveness of peripheral nerve stimulation
utilizing a subcutaneous lead implant technique plus op-
timized medical management (‘SQS arm’) versus optimal
medical management alone (‘OMM arm’). Patients with
back pain due to FBSS will be randomized to the SQS or
OMM arms. Patients that fail to achieve the primary
outcome (that is, ≥50% reduction in back pain intensity)
at 9 months post randomization will be allowed to
switch treatments. All patients will be followed up for 36
months post randomization.
The primary objective of SubQStim study is to com-
pare the proportion of patients achieving the primary
outcome at 9 months post randomization in SQS and
OMM arms. Secondary objectives are to: (1) compare
the primary outcome between SQS and OMM arms at 3
months and 6 months post randomization; (2) compare
secondary outcomes (functional disability, health-related
quality of life, patient satisfaction, patient global impres-
sion of change, healthcare utilization/costs, use of pain
mediation and non-invasive pain treatment) between
SQS and OMM arms at 3, 6 and 9 months postrandomization; (3) assess the value of trial stimulation in
predicting 9-month post-randomization primary out-
come response in the SQS arm; (4) assess the trend in
device programming parameters up to 9 months post
randomization; (5) assess within-patient changes (that is,
compared to baseline/prior to randomization) in primary
and secondary outcomes from 9 to 36 months post
randomization; (6) quantify the level of SQS-related and
non-SQS related adverse events at all follow-up timings
up to 36 months post randomization.
Methods/Design
Design and setting
Patients will be randomized 1:1 to peripheral nerve
stimulation utilizing a subcutaneous lead implant tech-
nique plus optimized medical management (‘SQS arm’)
or optimized medical management alone (‘OMM arm’)
and followed for 9 months (period I: randomized com-
parative period). At 9 months after randomization, if pa-
tients in either arm fail to meet certain criteria (see
below) they may switch treatment; that is, those in the
OMM arm receive SQS or those in the SQS arm have
their device turned off and/or explanted. Patients will be
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II: long-term follow-up period). The study design is
summarized in Figure 1.
The SubQStim study will be conducted in specialized
investigational centers. The principal investigator in each
site will be experienced in implanting spinal cord stimu-
lation systems and/or SQS systems or specializes in the
diagnosis and ongoing treatment of back pain (for
example, pain management physician, anesthesiologist,
neurosurgeon, and orthopedic surgeon). It is anticipated
that approximately 33 centers (30 European site and 3
Australian sites) will participate. No single center can
exceed 15% of the total evaluable patients (that is, pa-
tients with assessment of the primary outcome).Selection of patients
The target population is patients experiencing intract-
able chronic back pain due to FBSS.Figure 1 Study design.At the screening visit, patients will be assessed to de-
termine if they meet all of the inclusion criteria and are,
therefore, eligible to participate in the study. Potential
patients who meet any of the exclusion criteria will not
be eligible to participate in the study.
Inclusion criteria
Inclusion criteria are: signed and dated the Patient In-
formed Consent/Patient Information Sheet prior to any
study-related activities being conducted; ≥18 years of age
at time of informed consent; minimum average back
pain intensity of ≥50 mm assessed by VAS at screening
visit; willing and available to attend visits as scheduled
and to comply with the study protocol; willing and able
to undergo assessments as part of the evaluation for eligi-
bility and endpoints; willing and able to use the external
neurostimulator, recharging equipment (if applicable), and
patient programmer per the schedule required by the
protocol; diagnosed as having FBSS, that is, has had
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tomically correct, successful surgery and there are no fur-
ther therapeutic surgical options available as assessed by
appropriate investigation; based on the opinion of the
Principal Investigator, patient’s back pain is considered in-
tractable and has been adequately treated, as defined by:
failed an appropriate trial of at least three different
classes of back pain treatments (pharmaceutical and/or
non-pharmaceutical); based on the opinion of the
implanting physician, an appropriate implant candidate
for the SQS system.
Exclusion criteria
Exclusion criteria are: has been or is being treated with
spinal cord stimulation, subcutaneous nerve stimulation,
peripheral nerve stimulation or an implantable intrathecal
drug delivery system; leg pain score >30 mm assessed by
VAS at screening visit; evidence of an active disruptive
psychiatric disorder that is significant enough to impact
the perception of pain, compliance to intervention and/or
ability to evaluate treatment outcome, as determined by
the investigator; pain condition unrelated to FBSS that is
severe enough to overshadow the FBSS pain in the opin-
ion of the investigator; evidence of a spinal instability or
anatomic compression that requires further surgery; spinal
fusion at more than three vertebral levels; currently en-
rolled in or plans to enroll in any concurrent drug and/or
device study that may confound the results of this study;
allergic or has shown hypersensitivity to any materials of
the device system which come in contact with the body;
history of coagulation disorder or lupus erythematosus; in-
volved in current litigation regarding back pain.
Patients meeting the inclusion/exclusion criteria will
complete a baseline diary questionnaire for 7 days. Dur-
ing the baseline diary, the subject must: (1) report an
average back pain score ≥50 mm, (2) report an average
leg pain score ≤30 mm, and (3) complete the diary for at
least 5 days.
Interventions
Patients randomized to both arms will have their med-
ical management optimized during the 9-month treat-
ment period, beginning at randomization. Optimized
medical management for each subject will be defined by
the investigator. Optimized medical management does
not include back reoperation or the implantation of
medical devices (for example, neurostimulation or intra-
thecal drug delivery). For example, this may include
physiotherapy, transcutaneous electrical nerve stimula-
tion, pharmaceutical treatments or acupuncture.
Patients randomized to the SQS arm will undergo a
test stimulation implant and an at-home trialing period.
During the trialing period, patients will be programmed
according to their optimal programming parameters andwill be able to adjust their stimulation via the patient
programmer, within the settings programmed by the
physician. Prior to the permanent implant, all implanted
patients will discuss the trialing period with the principal
physician and complete a VAS for both back and leg
pain. A stimulation trial is only considered successful if
the following occurs: the patient agrees to proceed with
the permanent implant and finds the feeling of paresthesia
comfortable and has a pain reduction of ≥30% as mea-
sured by VAS or some reduction in pain as measured by
VAS, along with improved function, and/or improved
health-related quality of life, and/or a reduction in pain
medications as assessed by the principal investigator.
Given the lack of evidence of the predictive value of a
stimulation trial [24], we choose a trial cut off of 30% (ra-
ther than the conventional 50%) to enable a larger per-
centage of patients to progress to permanent implant. All
SQS arm subjects who had successful trial stimulation,
will be implanted with a neurostimulator (Medtronic, Inc.,
Minneapolis, MN, USA).. The final system implanted will
consist of a Medtronic pulse generator (rechargeable or
primary cell) attached either directly or via extension cable
to two subcutaneous leads (quadripolar or octopolar). Pa-
tients should receive their permanent implant within 10
weeks of randomization. In the event that a patient does
not proceed with the permanent implant, the patient will
stay in the study and will be followed according the sched-
uled visits, unless the patient withdraws consent.
The following SQS-related equipment will be used in
this study: The RestoreAdvancedW, PrimeAdvancedW,
RestoreUltraW, and RestoreSensorW neurostimulators, 1
× 8 Standard and Quad PlusW leads (all Medtronic, Inc.,
Minneapolis, MN, USA)., and all current commercially
available internal and external accessories approved for
use for Peripheral Nerve Stimulation, and all future
commercially available Medtronic neurostimulation de-
vices, leads and accessories approved for use for Periph-
eral Nerve Stimulation.
Treatment switch criteria
The investigator criteria to inform patient treatment
switch after 9 months post randomization or later are as
follows: if <30% pain relief on VAS: switchover is nor-
mally allowed without any further justification; if 30% to
50% pain relief on VAS: switchover is normally allowed
if the patient has another reason for not responding to
randomized arm, such as: no perceived improvement in
quality of life, disability or medication use and/or side
effects from treatments; if >50% pain relief on VAS:
switchover is normally not allowed.
Assessments
Patients will be assessed prior to randomization (base-
line) and at follow-up visits at 3, 6, 9, 12, 18, 24, 30 and
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that patients visit the local investigational center and
have their data collected via an electronic case report
form. Table 3 provides a summary of the data collection
process and timing.
Primary outcome
The proportion of subjects with a ≥50% reduction in
back pain intensity (VAS) from baseline to the 9 months
post randomization. Patients will complete a pain diary,
comprising a VAS scale, three times daily during the 7
days prior to their visit. The average VAS during that
period will be calculated as the ratio between the sum of
recorded VAS and the number of VAS measured. The per-
centage pain reduction will be calculated as 100*(VAS0-
VASV)/VAS0, where VAS0 is the average VAS at baseline
visit and VASv is the average VAS at subsequent visits.
Secondary outcomes
Secondary outcomes are: pain relief: ≥50% back pain re-
lief at all visits in addition to 9 months, ≥30% back pain
relief at all time points; pain intensity score: back and
leg VAS score via patient diary at all time points; func-
tional disability: Oswestry Disability Index (ODI) version
2 [24] at all time points; health-related quality of life:
Short-Form 36 (SF-36) [25] and EQ-5D-5 L [26] at all
time points; patient satisfaction (‘are you satisfied with
the pain relief provided by your treatment?’ and ‘based
on your experience so far, would you have agreed to this
treatment?’) [7] at all follow-up time points; Patient Global
Impression of Change (PGIC) [27] at all follow-up time
points; healthcare utilization (HCU), that is, concomitant
drug treatment for pain relief (opioid, non-steroidal anti-
inflammatory drugs (NSAIDs), antidepressant drugs, anti-
convulsants), need for physical therapy or other non-drug
treatments) [28] at all time points; adverse events: both
device-related and non-device-related adverse events and
complications will be collected. The nature and frequency
of events will be documented and an Adverse Events
Committee will adjudicate all events.
Process measures
At the screening and baseline visits, the following add-
itional information will be collected: patient demographics
(for example, age, gender, duration of back pain), neuro-
pathic pain severity (Douleur Neuropathique en 4 Ques-
tions (DN4)), [29] mood (Hospital Anxiety and Depression
Scale (HADS)) [30] and level of previous healthcare
utilization. Patients who proceed to device implantation
will have the following information collected: back pain
and paresthesia maps, radiographic images, parameter set-
tings, lead location, and device implant information (that
is, model, serial number). At subsequent visits, clinical and
patient programmer data will be downloaded. All medicaland alternative treatments received as optimized medical
management will be recorded at each follow-up visit.
Unscheduled patient visits could occur between sched-
uled study follow-up visits for the following reasons: patient
discontinuation from the study, device reprogramming and
management of device-related complications, or revisions
of non-device treatment.
Sample size and power calculations
A 20% difference in the primary outcome between the
SQS and OMM arms is considered relevant. Assuming
that 40% of the patients receiving OMM alone achieve
the primary outcome, the study needs to recruit a total
of 350 patients to detect a clinically important difference
at the 5% alpha level and 90% power allowing for 20%
attrition. However, it is expected that the difference
between the two arms of the trial may be larger, that is,
25% or 30%. Two interim analyses are, therefore, planned
at 140 and 220 evaluable patients (that is, with completed
primary outcome) to provide 80% power in order to detect
a 30% difference, and 85% power to detect a 25% differ-
ence (respectively), at 2-sided 1% alpha level. In order to
ensure an overall alpha of two-sided 5%, the final analysis
will be performed at two-sided 3% alpha [31]. In order to
undertake 2 interim analyses and a final analysis, a total of
400 patients (N = 200 SQS arm and N = 200 OMM arm)
will be required. These interim and final analyses are sum-
marized in Table 4.
Procedures to minimize bias
Computer generated random allocation schedules will
be preprepared for each investigational center. The
randomization schedule will be centrally held and alloca-
tion concealment will be maintained by an online data-
base system that automatically assigns the patient to one
of the two arms on confirmation by research nurse at
the end of the baseline visit. The randomization sched-
ules will be stratified to maintain a 1:1 balance between
the treatment and control arm within each center and in
the study as a whole. Patients will be randomized se-
quentially based upon randomization date and time.
Given the nature of both the intervention and control
treatments, it is unfortunately not possible to blind ei-
ther patients, or clinicians.
If a patient misses a study visit, the center’s study staff
will make three attempts (one in writing and sent via a
traceable method) to bring them in for a study visit. The
numbers and reasons for dropouts and losses to follow-
up will be reported by each arm of the study.
All study deviations (that is, an event where the inves-
tigator, or center personnel, did not conduct the study
according to the Clinical Investigational Plan, Protocol,
or Clinical Investigation Agreement) will be recorded
and the reasons documented.
Table 3 SubQStim study: summary of data collection
Study
requirements
Screening Baseline Test
stimulation
implant
Permanent
implant
Wound
check
1 month 3 months 6 months 9 months 12 months 18 and
24 months
30 and
36 months
Unscheduled Discontinued
Patient informed
consent/patient
information sheet
X
Screening
inclusion/
exclusion criteria
X
Demographics X
Physical
examination
X
Medical history X
HCU history X
VAS (point in time
measurement
only)
X X X
Back pain map X Xa Xa X X X X X X X X X X
Paresthesia map
(implanted
subjects only)
X Xa X X X X X X X X X X
Confirmation of 7-
day baseline dairy
inclusion criteria
X
Randomization
assignment (after
questionnaires)
X
HADS X
painDETECT X
EQ-5D X X X X X X X X X
ODI X X X X X X X
SF-36 X X X X X X X
PGIC X X X X X X X X X
Implant
information
Xa Xa
Postoperative
radiography
X
Subject
satisfaction
X X X X X X X X
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Table 3 SubQStim study: summary of data collection (Continued)
7-day diary
completion
X X X X X X
Initial and final
interrogations and
uploads
X X X X X X X X X X X X
Medication
assessment
X X X X X X X X X X X X X
Protocol
deviations
X X X X X X X X X X X X X
Event assessment
(adverse events)
X X X X X X X X X X X X X
HCU X X X X X X X X X X X X X
EQ-5D EuroQoL five dimensions, HADS Hospital Anxiety and Depression Scale, HCU healthcare utilization, ODI Oswestry Disability Index, PGIC Patient Global Impression of Change, SF-36 Short-Form 36, VAS visual
analog scale. aPre-implant and post-implant as indicated; otherwise, post-implant or post-reprogramming only.
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Table 4 SubQStim study: sample size and power calculations
Analysis Expected difference
between groups
Power
(1-β)
Nominal error
risk (α)
Proportion of responders Sample size
OMM arm SQS arm Evaluable patientsa Enrolled
(20% attrition rate)
Interim 1 30% 80% 1% 35% 65% 140 176
Interim 2 25% 85% 1% 37.5% 62.5% 220 276
Final 20% 90% 3% 40% 60% 314 392
For reference:
one-shot analysis
20% 90% 5% 40% 60% 280 350
aPatients with completed primary outcome data.
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Statistical analysis
The intent-to-treat patient set (ITT) consists of all
patients as they were randomized into the study. The
per-treatment patient set (PT) consists of all patients of
the ITT patient set for whom no major protocol devi-
ation was reported. Patients who underwent a treatment
switch, that is, who had initially been randomized to the
OMM arm and switched to the SQS arm, or vice versa,
will be included in this patient set. They will be analyzed
according to treatment actually received.
The primary effectiveness analysis will be based on a
between group comparison of primary and secondary
outcomes up to, and including, the 9-month visit using
the ITT patient data set [32]. For continuous outcomes,
analytic models will be adjusted for baseline outcome
score.
Sensitivity analyses will be undertaken using the same
analytic models used in the primary analysis and based
on the PT data set. In case of a discrepancy between the
two analyses, a closer analysis of the data, of those
patients from which the discrepancies result, will be
performed. An additional sensitivity ‘modified ITT’ ana-
lysis will be performed for the primary outcome, consid-
ering patients randomized to the SQS arm but not
definitively implanted as ‘failures’.
In phase II of the study (beyond 9-month visit) the ana-
lytic focus will be a within-person approach, that is, com-
parison of primary and secondary outcomes at follow-up,
relative to baseline. In addition, the percentage of subjects
who switched treatments after the 9-month follow-up
visit, and the time to switchover, will be compared be-
tween OMM and SQS arms.
The study will seek to minimize missing data by
conducting completeness checks on study data and pa-
tient questionnaires, with follow-up on any missing data.
It is not possible to predict which will be the most ef-
fective method, therefore, we will undertake sensitivity
analyses to examine different methods of missing data
imputation, such as mean of nearby points (moving
average), last value carried forward, doubly robust esti-
mators or the best or the worst values that are not in
favor of the SQS arm [33,34].The ‘safety patient set’ consists of all patients of the
ITT dataset, who started any of the study procedures in-
dependent of the treatment they had been randomized
to. Complications and adverse events will be reported
descriptively.
All statistical tests will be interpreted at the two-sided
α = 5% level and results reported as means and 95%
confidence intervals. A more detailed exposition of study
statistical analyses will be presented in a Statistical Ana-
lysis Plan to be completed prior to any data analysis.
Economic evaluation
Economic analysis alongside the RCT will estimate the
cost effectiveness of SQS plus OMM versus OMM
alone. The primary economic endpoints will be the cost
per quality-adjusted life-years (QALYs) gained, and cost
per additional unit of change in the primary outcome
(that is, per unit change in pain VAS and change in pro-
portion with ≥50% reduction in back pain intensity). Pri-
mary economic analyses will be at 9-month follow-up,
with secondary analyses comparing costs over longer-term
follow-up. Cost-effectiveness analyses will be undertaken
using the perspective of a third party payer, for example,
health service provider/payer perspective.
Within-trial data collection will inform estimates of
intervention related resource, and resource use data will
be combined with appropriate unit costs to estimate
SQS intervention costs, in addition to OMM. Estimates
of costs associated with other resource use will be in-
formed by the HCU data collected within trial. Partici-
pant self-report data on EQ-5D-5 L [25] and SF-36 [26]
will be combined with country specific tariffs to estimate
health state values, and mean (and standard deviation)
health state value for each arm at assessment point. The
EQ-5D-5 L will be used as the primary outcome meas-
ure for health state values, with SF-36 (SF-6D, a utility
score calculated from SF-36) used in sensitivity analyses.
Health state values will be used to estimate QALY data
over appropriate time periods. QALY data will be esti-
mated using the area under the curve approach [35].
Comparison of costs, mean health state value, and QALY,
over time will be adjusted for baseline value consistent
with the statistical analysis plan.
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longer time horizon, future costs and outcomes will be
discounted at rates appropriate for country level ana-
lyses. Analyses of costs and outcomes will consider
uncertainty in parameter estimates, assumptions (for
example, device lifetime), and limitations with the data,
using extensive sensitivity analyses. The net benefit statis-
tic will be used to present cost-effectiveness acceptability
curves and confidence intervals on cost effectiveness
against a range of estimates of willingness to pay per add-
itional unit of outcome (for example, cost per QALY
threshold values) [36,37].
Ethics and governance
Prior to enrolling subjects in this study, each investiga-
tion center’s Medical Ethical Committee will be required
to approve the current study Clinical Investigation Plan
and the Patient Information and Informed Consent Form.
Any other written information to be provided to the sub-
jects and, if applicable, any materials used to recruit sub-
jects will also require ethical approval. Furthermore, such
approval must be received in the form of a letter and pro-
vided to the study Sponsor (Medtronic Inc.) before com-
mencement of the study at an investigation center.
At each center, investigators must obtain written in-
formed consent prior to subjecting patients to any study
related activity.
An independent Adverse Event Committee will review
all adverse events. This Committee will consist of a
minimum of three physicians independent of the Spon-
sor. The responsibilities of the Adverse Event Committee
include, but are not limited to, the following: review all
reported adverse events and their classification on a peri-
odic basis; upon request, advise the Sponsor about the po-
tential clinical impact of an observed, unintended device
performance and cases of serious adverse device events.
Finally, clinical monitors, as a representative of the
Sponsor, will visit the principal investigators and/or
subinvestigators and study centers at periodic intervals
to ensure compliance to the investigational plan and
study agreements, adherence to current International
Organization for Standardization, Declaration of Helsinki
regulations and standard operational procedures, and
check accuracy of study data.
Discussion
RCTs have provided evidence to indicate spinal cord
stimulation to be a clinically effective adjunct to medical
management, and an alternative to a further operation
for patients experiencing FBSS [7,8]. Given this level I
evidence, payers such as the National Institute for
Health and Clinical Excellence (NICE) in the UK have
recommended SCS as both a clinically and cost-effective
therapy for the management of FBSS [38-40].Nevertheless, while chronic leg (or radicular) pain can
be effectively treated with SCS, this therapy is not always
sufficient for chronic back pain. The existing trials of
spinal cord stimulation in patients with FBSS, recruited
individuals who presented with predominant leg pain
and excluded those with predominant back pain [7,8].
Our systematic review identified 9 cases series studies of
SQS in a total of 191 patients with chronic back pain. Im-
portantly, these studies show that SQS implantation can
result in clinically significant levels of pain relief in pre-
dominant back pain that is due to FBSS. The SubQStim
study is the first RCT to assess the effectiveness and cost
effectiveness of SQS in this patient population.
Trial status
The SubQStim trial began patient recruitment in November
2012. Recruitment is expected to close in late 2014. It is
anticipated that primary endpoint findings will be avail-
able in approximately 2016.
Additional file
Additional file 1: Figure S1. Systematic review: summary of study
selection. Table S1. Systematic review: quality assessment.
Abbreviations
CBLP: Chronic back and leg pain; CE: Conformité Européenne (European
Conformity); DN4: Douleur Neuropathique en 4 Questions; FBSS: Failed back
surgery syndrome; HADS: Hospital Anxiety and Depression Scale;
HCU: Healthcare utilization; ITT: Intention to treat; LBP: Low back pain;
MR: Magnetic resonance; ODI: Oswestry Disability Index; OMM: Optimal
medical management; NSAIDs: Non-steroidal anti-inflammatory drugs;
PGIC: Patient Global Impression of Change; PT: Per treatment;
RCT: Randomized controlled trial; SF-36: Short-Form 36; SQS: Subcutaneous
nerve stimulation; VAS: Visual analog scale; WHO: World Health Organization.
Competing interests
SE, CG, MK, WP and RST have received consultancy fees from Medtronic. KW
is a full-time employee of Medtronic.
Authors’ contributions
SE is the overall study principal investigator. All authors are member of the
SubQStim Trial Steering Committee and have participated in the study
conception and design. All authors contributed to the writing of the study
protocol and the drafting and editing of this manuscript. All authors read
and approved the final manuscript.
Acknowledgements
The study is funded by Medtronic Inc. Aptiv Solutions provide trial support.
Rebecca Taylor (consultant researcher, Honiton, Devon, EX14 3JJ, UK) acted
as the second reviewer for the SQS systematic review.
Author details
1The James Cook Hospital, Middlesbrough, UK. 2Elisabethinen Hospital, Graz,
Austria. 3Leiden University Medical Center and Medical Center, The Hague,
The Netherlands. 4Exeter Medical School, University of Exeter, Exeter, UK.
5Medtronic, Inc, Tolochenaz, Switzerland. 6Institute of Health Services
Research, University of Exeter Medical School, Veysey Building, Salmon Pool
Lane, Exeter EX2 4SG, UK.
Received: 2 December 2012 Accepted: 5 June 2013
Published: 25 June 2013
Eldabe et al. Trials 2013, 14:189 Page 12 of 12
http://www.trialsjournal.com/content/14/1/189References
1. Waddell G: The Back Pain Revolution. London, UK: Churchill Livingstone;
1998.
2. Manca A, Eldabe S, Buchser E, Kumar K, Taylor RS: Relationship between
health-related quality of life, pain, and functional disability in
neuropathic pain: patients with failed back surgery syndrome.
Value Health 2010, 13:95–102.
3. Doth A, Hansson PS, Jensen MP, Taylor RS: The burden of neuropathic
pain: a systematic review and meta-analysis of health utilities. Pain 2010,
149:338–344.
4. Maniadakis N, Gray A: The economic burden of back pain in the UK.
Pain 2000, 84:95–103.
5. North R, Shipley J, Prager J, Barolat G, Barulich M, Bedder M, Calodney A,
Daniels A, Deer T, DeLeon O, Drees S, Fautdch M, Fehrenbach W,
Hernandez J, Kloth D, Krames ES, Lubenow T, North R, Osenbach R, Panchal
SJ, Sitzman T, Staats P, Tremmel J, Wetzel T, American Academy of Pain
Medicine: Practice parameters for the use of spinal cord stimulation in
the treatment of chronic neuropathic pain. Pain Med 2007,
8(Suppl 4):S200–S275.
6. Oakley JC: Spinal cord stimulation in axial low back pain: solving the
dilemma. Pain Med 2006, 7:C58–C63.
7. Kumar K, Taylor RS, Jacques L, Eldabe S, Meglio M, Molet J, Thomson S,
O'Callaghan J, Eisenberg E, Milbouw G, Buchser E, Fortini G, Richardson J, North
RB: Spinal cord stimulation versus conventional medical management for
neuropathic pain: a multicentre randomised controlled trial in patients
with failed back surgery syndrome. Pain 2007, 132:179–188.
8. North RB, Kidd DH, Olin J, Sieracki JM, Farrokhi F, Petrucci L, Cutchis PN:
Spinal cord stimulation for axial low back pain: a prospective, controlled
trial comparing dual with single percutaneous electrodes. Spine 2005,
30:1412–1418.
9. Stanton-Hicks M, Panourias IG, Sakasb D, Slavinc KV: The future of
peripheral nerve stimulation. Prog Neurol Surg 2011, 24:210–217.
10. Wall PD, Sweet WH: Temporary ablation of pain in man. Science 1967,
155:108–109.
11. Levy RM: Differentiating the leaves from the branches in the tree of
neuromodulation: the state of peripheral nerve field stimulation.
Neuromodulation 2011, 14:201–205.
12. Campbell JN, Long DM: Peripheral nerve stimulation in the treatment of
intractable pain. J Neurosurg 1976, 45:692–699.
13. Paicius RM, Bernstein CA, Lempert-Cohen C: Peripheral nerve field
stimulation for the treatment of low back pain: preliminary results of
long-term follow-up: a case series. Neuromodulation 2007, 10:279–290.
14. Sator-Katzenschlager S, Fiala K, Kress HG, Kofler A, Neuhold J, Kloimstein H,
Ilias W, Mozes-Balla EM, Pinter M, Loining N, Fuchs W, Heinze G, Likar R:
Subcutaneous target stimulation (STS) in chronic noncancer pain: a
nationwide retrospective study. Pain Pract 2010, 10:279–286.
15. Verrills P, Mitchell B, Vivian D, Sinclair C: Peripheral nerve stimulation: a
treatment for chronic low back pain and failed back surgery syndrome?
Neuromodulation 2009, 12:68–75.
16. Falco FJ, Berger J, Vrable A, Onyewu O, Zhu J: Cross-talk: a new method
for peripheral nerve stimulation. Pain Physician 2009, 12:965–983.
17. Burgher AH, Huntoon MA, Turley TW, Doust MW, Stearns LJ: Subcutaneous
peripheral nerve stimulation with inter-lead stimulation for axial neck
and low back pain: case series and review of the literature.
Neuromodulation 2012, 15:100–106.
18. Verrills P, Vivian D, Mitchell B, Barnard A: Peripheral nerve field stimulation
for chronic pain: 100 cases and review of the literature. Pain Med 2011,
12:1395–1405.
19. Verrills P, Mitchell B, Vivian D, Sinclair C: Peripheral nerve field stimulation:
is age an indicator of outcome? Neuromodulation 2009, 12:60–67.
20. Yakovlev AE, Resch BE, Yakovleva VE: Peripheral nerve field stimulation in
the treatment of postlaminectomy syndrome after multilevel spinal
surgeries. Neuromodulation 2011, 14:534–538.
21. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT,
Haythornthwaite JA, Jensen MP, Kerns RD, Ader DN, Brandenburg N, Burke
LB, Cella D, Chandler J, Cowan P, Dimitrova R, Dionne R, Hertz S, Jadad AR,
Katz NP, Kehlet H, Kramer LD, Manning DC, McCormick C, McDermott MP,
McQuay HJ, Patel S, Porter L, Quessy S, Rappaport BA, et al: Interpreting the
clinical importance of treatment outcomes in chronic pain clinical trials:
IMMPACT recommendations. J Pain 2008, 9:105–121.22. Taylor RS, Buscher E, Van Buyten J-P: Spinal cord stimulation for chronic
back and leg pain and failed back surgery syndrome: a systematic
review and analysis of prognostic factors. Spine 2005, 30:152–160.
23. North R, Shipley J, Prager J, Barolat G, Barulich M, Bedder M, Calodney A,
Daniels A, Deer T, DeLeon O, Drees S, Fautdch M, Fehrenbach W,
Hernandez J, Kloth D, Krames ES, Lubenow T, North R, Osenbach R, Panchal
SJ, Sitzman T, Staats P, Tremmel J, Wetzel T: Practice parameters for the
use of spinal cord stimulation in the treatment of chronic neuropathic
pain. Pain Med 2007, 8(Suppl 4):S200–S275.
24. Fairbank J, Pynsent P: The Oswestry disability index. Spine 2000, 25:2940–2953.
25. McHorney CA Jr, Ware JE, Raczek AE: The MOS 36-item Short-Form Health
Survey (SF-36): II. Psychometric and clinical tests of validity in measuring
physical and mental health constructs. Med Care 1993, 31:247–263.
26. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia
X: Development and preliminary testing of the new five-level version of
EQ-5D (EQ-5D-5L). Qual Life Res 2011, 20:1727–1736.
27. Hurst H, Bolton J: Assessing the clinical significance of change scores
recorded on subjective outcome measures. J Manipulative Physiol Ther
2004, 27:26–35.
28. Manca A, Kumar K, Taylor RS, Jacques L, Eldabe S, Meglio M, Molet J,
Thomson S, O'Callaghan J, Eisenberg E, Milbouw G, Buchser E, Fortini G,
Richardson J, Taylor RJ, Goeree R, Sculpher MJ: Quality of life, resource
consumption and costs of spinal cord simulation versus conventional
medical management in neuropathic pain patients with failed back
surgery syndrome (PROCESS trial). Eur J Pain 2008, 12:1047–1058.
29. Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, Cunin G,
Fermanian J, Ginies P, Grun-Overdyking A, Jafari-Schluep H, Lantéri-Minet M,
Laurent B, Mick G, Serrie A, Valade D, Vicaut E: Comparison of pain
syndromes associated with nervous or somatic lesions and development
of a new neuropathic pain diagnostic questionnaire (DN4). Pain 2005,
114:29–36.
30. Zigmond A, Snaith R: The hospital anxiety and depression scale. Acta
Psych Scand 1983, 67:361–370.
31. Bender R, Lange S: Adjusting for multiple testing - when and how? J Clin
Epidemiol 2001, 54:344–349.
32. Schulz K, Altman DG, Moher D, CONSORT Group: CONSORT 2010
statement: updated guidelines for reporting parallel group randomized
trials. Ann Intern Med 2010, 152:1–6.
33. White IR, Horton NJ, Carpenter J, Pocock SJ: Strategy for intention to treat
analysis in randomised trials with missing outcome data. BMJ 2011, 342:d40.
34. Bang H, Robins J: Doubly robust estimation in missing data and causal
inference models. Biometrics 2005, 61:962–972.
35. Brazier J, Ratcliffe J, Salomon JA, Tsuchiya A: Measuring and Valuing Health
Benefits for Economic Evaluation. Oxford, UK: Oxford University Press; 2007.
36. Hoch JS, Briggs AH, Willan AR: Something old, something new, something
borrowed something blue: a framework for the marriage of health
econometrics and cost-effectiveness analysis. Health Econ 2002, 11:415–430.
37. Van Hout BA, Al MJ, Gordon GS, Ruten FFH: Costs, effects and C/E-ratios
alongside a clinical-trial. Health Econ 1994, 3:309–319.
38. National Institute for Health and Clinical Excellence (NICE): Spinal Cord
Stimulation for Chronic Pain of Neuropathic or Ischaemic Origin. London, UK:
National Institute for Health and Clinical Excellence; 2008.
39. Simpson EL, Duenas A, Holmes MW, Papaioannou D, Chilcott J: Spinal cord
stimulation for chronic pain of neuropathic or ischaemic origin:
systematic review and economic evaluation. Health Technol Assess 2009,
13:1–154.
40. Taylor RS, Ryan J, O'Donnell R, Eldabe S, Kumar K, North RB: The cost-
effectiveness of spinal cord stimulation in the treatment of failed back
surgery syndrome. Clin J Pain 2010, 26:463–469.
doi:10.1186/1745-6215-14-189
Cite this article as: Eldabe et al.: Assessing the effectiveness and cost
effectiveness of subcutaneous nerve stimulation in patients with
predominant back pain due to failed back surgery syndrome (SubQStim
study): study protocol for a multicenter randomized controlled trial.
Trials 2013 14:189.
